Blake A. Morrison, PharmD, vice president, Medical and Scientific Affairs, Multiple Myeloma Research Foundation, discusses adverse events associated with new agents to treat patients with multiple myeloma.
Blake A. Morrison, PharmD, vice president, Medical and Scientific Affairs, Multiple Myeloma Research Foundation, discusses adverse events associated with new agents to treat patients with multiple myeloma. We spoke with Morrison at the 2015 ASH Annual Meeting in December.
New agents such as elotuzumab (Empliciti) and daratumumab (Darzalex)—which were approved in November—seem promising and to have a good overall side effect profile, Morrison says.
There is, however, a risk of infusion reaction with the first exposure. These reactions can be significantly uncomfortable for patients and can be long-lasting, Morrison says. Nurses should be aware of these reactions and look for them when they have a patient in the infusion chair.
Survival Benefit, Durable Responses Continue at 3 Years With Liso-cel in Second-line LBCL
July 15th 2024Three-year findings from the TRANSFORM trial provide further evidence that liso-cel should be considered as the new standard of care along with other CAR T-cell therapies for patients with primary refractory or relapsed LBCL, an expert said.